ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen Boorjian, MD
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- Keck School of Medicine at Usc Medical Center
Los Angeles, California, United States
- the Urology Center of Colorado
Denver, Colorado, United States
- University of Florida - Uf Health Davis Center Pavilion and Shands Med Plaza
Gainesville, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- Emory University School of Medicine
Atlanta, Georgia, United States
- University of Chicago - Comprehensive Cancer Research Center
Chicago, Illinois, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Spectrum Health Medical Group
Grand Rapids, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Mayo Clinic - Rochester
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Delaware Valley Urology, Llc
Voorhees Township, New Jersey, United States
- Suny Upstate Medical Center
Syracuse, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- University of North Carolina (unc) - Chapel Hill
Chapel Hill, North Carolina, United States
- Duke University
Durham, North Carolina, United States
- the University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
- the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Regional Urology
Greenville, South Carolina, United States
- Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
- Vanderbilt University Medical Center Dept. of Urologic Surgery
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- Baylor College of Medicine
Houston, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- the Univ. of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
- University of Virginia Health System
Charlottesville, Virginia, United States
- Urology of Virginia
Virginia Beach, Virginia, United States
- West Virginia University Cancer Institute
Morgantown, West Virginia, United States
- University of Wisconsin - Madison
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Sept 2016
- Primary completion
- 24 May 2019
- Completion
- 24 May 2023
- Last update posted
- 29 Jul 2024
- Registered enrollment
- 157
- Registry id
- NCT02773849
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.